Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05008081Recruiting

The CATALINA Study

Role: lead

NCT02205255Phase 3Completed

BACE Trial Substudy 2 - FarmEc Substudy

Role: lead

NCT02205242Phase 3Completed

BACE Trial Substudy 1 - PROactive Substudy

Role: lead

NCT02135354Phase 3Terminated

Azithromycin for Acute Exacerbations Requiring Hospitalization

Role: lead

NCT02332122Unknown

Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis

Role: lead

All 5 trials loaded